Research Article

Impact of BMI on Long-Term Outcomes in Patients with ST-Segment Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention

Table 2

Persistence with therapy and lifestyle characteristics after discharge for younger and older STEMI groups.

≤65 y value>65 y value
BMIBMI
NormalOverweightObesityNormalOverweightObesity
<24 (n = 168)24–28 (n = 596)>28 (n = 228)<24 (n = 50)24–28 (n = 198)>28 (n = 189)

Medication adherence
 Aspirin118 (70.2)488 (81.9)198 (86.8)<0.0142 (84.0)174 (87.9)150 (79.4)0.196
 ACEI/ARB32 (19)120 (20.1)48 (21.1)0.66018 (36.0)38 (19.2)48 (25.4)0.035
 Beta-blockers68 (40.5)228 (38.3)96 (42.1)0.29820 (30.0)92 (46.5)66 (34.9)0.284
 Statin96 (57.1)400 (67.1)156 (68.4)<0.0138 (76.0)146 (73.3)102 (54.0)0.012
Lifestyle
 Smoking cessation24 (14.3)80 (13.4)24 (10.5)0.4556 (10.7)54 (27.3)33 (17.5)0.009
 Regular exercise112 (66.7)332 (55.7)114 (50.0)0.02034 (68.0)120 (60.6)96 (50.8)0.885
 Diet, reduced fried foods and meat48 (28.6)192 (32.2)96 (42.1)0.11110 (20.0)90 (45.5)48 (25.4)0.002
 Sleeping time6.7 ± 1.36.9 ± 1.26.8 ± 1.10.0227.2 ± 1.17.2 ± 1.47.1 ± 1.20.702

BMI, body mass index; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers.